A pH-responsive curcumin cross-linked micelle and its preparation method and application
Through the interaction of pH-responsive curcumin cross-linked micelles and cell membranes, rapid endocytosis and transcytosis of drugs are achieved, solving the problem of short drug circulation time and side effects of curcumin in the treatment of atherosclerosis, and improving the drug The load capacity and delivery efficiency achieve efficient and fixed-point treatment.
Patent Information
- Application Number
- CN202410902928.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-08
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2044-07-08
AI Technical Summary
The existing curcumin treatment of atherosclerosis has problems such as short drug circulation time, unspecific distribution, low drug utilization rate and side effects, making it difficult to achieve effective targeted treatment.
Using pH-responsive curcumin cross-linked micelles, the interaction between N-oxide zwitterionic polymer and cell membrane can achieve rapid endocytosis and transcytosis of drugs, improve the deep penetration ability of drugs, and in acidity Achieving targeted drug release in a microenvironment.
It improves the load and delivery efficiency of the drug, reduces systemic side effects, and realizes efficient and fixed-point delivery of the drug to the lesion site, enhancing the treatment effect.
Smart Images

Figure CN118440362B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology, and in particular relates to a pH-responsive curcumin cross-linked micelle and a preparation method and application thereof. Background Art
[0002] Atherosclerosis (AS) is an age-related disease characterized by elevated levels of reactive oxygen species (ROS) and chronic inflammation. The mainstay of treatment is lipid-lowering with statins, which can be associated with side effects. Anti-inflammatory, antioxidant, and immunomodulatory drugs have limitations as new therapeutic strategies, such as side effects due to systemic distribution. Drug delivery systems (DDS) are an alternative strategy that can be used to overcome these limitations, as they enable site-specific delivery, improve therapeutic efficacy, and reduce systemic side effects of drugs. In addition to the enhanced vascular permeability exhibited by the dysfunctional endothelial wall, which promotes the extravasation and accumulation of nanocarriers (NCS) within AS lesions, the expression of inflammatory biomarkers and adhesion molecules by different cellular components of the plaque can be exploited to specifically target atherosclerotic plaques. On the other hand, chronic inflammation associated with AS is characterized by an acidic microenvironment that can be exploited to achieve pH-responsive drug release at the site of injury.
[0003] Nanocarriers have unique advantages in assisting the combination chemotherapy of multiple types of drugs. Polymer micelles may dissociate due to large-scale dilution under normal physiological conditions, resulting in premature release of drugs. Cross-linked micelles improve stability and in vivo circulation time through covalent binding. Reversibly cross-linked micelles can release drugs in response to abnormal pH or redox environment of tumor tissue. Similar to traditional hydrophobic anti-inflammatory drugs, curcumin has problems such as short circulation time, non-specific distribution, and low drug utilization after oral or intravenous injection into the human circulation, which seriously hinders its clinical application. Simvastatin is one of the most commonly used lipid-lowering drugs, and its bioavailability is low due to its poor water solubility. In addition, side effects such as myopathy and liver damage also limit its clinical application. For this reason, the present invention proposes a pH-responsive curcumin cross-linked micelle, a preparation method and application thereof.
[0004] Zwitterionic nanomedicines can deeply penetrate cells, and N-oxide zwitterionic polymers can interact with the phospholipid hydrogen bonds of the cell membrane, allowing them to adhere to the cell membrane, thereby triggering rapid endocytosis and transcytosis, and improving the deep penetration ability of nanomedicines. Therefore, N-oxide zwitterionic polymers have the potential to solve the problem of drug enrichment in atherosclerotic sites. Summary of the invention
[0005] The object of the present invention is to provide a pH-responsive curcumin cross-linked micelle and a preparation method and application thereof, aiming to solve the problems raised in the above-mentioned background technology.
[0006] To achieve the above object, the present invention provides the following technical solutions:
[0007] A method for preparing pH-responsive curcumin cross-linked micelles comprises the following steps:
[0008] Step 1, weigh 5-hexynoic acid and dissolve it in 30 mL of anhydrous dichloromethane, weigh oxalyl chloride and dissolve it in anhydrous dichloromethane; add the oxalyl chloride solution dropwise to the 5-hexynoic acid at 0°C, and add DMF as a catalyst, react overnight after the addition, the solution changes from colorless to black, and then the solvent and excess oxalyl chloride are dried and dissolved in 30 mL of anhydrous dichloromethane; dissolve OPDA-HEMA in DMSO, slowly add the chlorinated 5-hexynoic acid solution dropwise to OPDA-HEMA under an argon atmosphere, and add triethylamine, continue to react for 24 hours after the addition, then remove the solvent, transfer the product to a dialysis bag, dialyze with deionized water for 72 hours, and freeze-dry to obtain a brown flocculent product, i.e., OPDA-HEMA-5HA;
[0009] Step 2: Dissolve OPDA-HEMA-5HA, Cur, SV and DMAP in 1 mL of methanol, stir at 37 °C for 24 h, then add the mixed solution dropwise into 10 mL of ice water under ultrasonic treatment, transfer the product to a dialysis bag, and dialyze with deionized water for 24 h to obtain OPDA-HEMA-5HA@Cur / SV.
[0010] Furthermore, the cutoff capacity of the dialysis bag in step 1 and step 2 is 3500Da.
[0011] Furthermore, the synthesis steps of the OPDA-HEMA are as follows: adding 30% aqueous hydrogen peroxide solution to PDA-HEMA, stirring at room temperature, then transferring the solution to a dialysis bag with a MWCO of 3000Da, and then dialyzing with deionized water, changing it every 3-4 hours, and freeze-drying to obtain a white flocculent product, namely OPDA-HEMA;
[0012] The synthesis steps of the PDA-HEMA are as follows: 2-2-bipyridine and CuCl are added in sequence to a multi-baked, vacuumed and argon-filled flask, and the flask is shaken back and forth to form a brick red complex, and then DEA, HEMA, ethyl 2-bromo-2-methylpropionate and DMF are added in sequence to the flask, and then polymerized at 55° C. for 3 hours in an argon atmosphere, and after the reaction stops, the flask is exposed to air and quenched by adding dichloromethane, and the filtrate is passed through a neutral alumina column to remove copper ions, and the filtrate is concentrated, and then precipitated with cold petroleum ether, repeatedly recrystallized and purified, and finally dried in a vacuum drying oven for 24 hours to obtain PDA-HEMA.
[0013] Furthermore, in the synthesis step of PDA-HEMA, the ratio of 2-2-bipyridine to CuCl is 0.1-0.6:0.3-1.
[0014] A pH-responsive curcumin cross-linked micelle prepared according to the preparation method described above.
[0015] A use of the pH-responsive curcumin cross-linked micelles described above in preparing a drug delivery system for treating atherosclerosis.
[0016] Compared with the prior art, the present invention has the following beneficial effects:
[0017] The present invention synthesizes cross-linked micelles with pH responsiveness, and Cur acts as both a drug and a cross-linking agent, which helps to improve the drug loading and delivery efficiency. The cross-linked micelles use nanotechnology to deliver drugs directly to the lesion site, improve the therapeutic effect and reduce systemic side effects. This strategy uses biomarkers, adhesion molecules and acidic microenvironment specific to the atherosclerotic plaque area to achieve targeted drug release. The characteristics of the cross-linked micelles include: excellent stability when diluted with water; cleavage into smaller micelles in an acidic environment, which is conducive to drug release; higher drug loading and higher drug delivery efficiency compared to non-cross-linked micelles; because OPDA-HEMA-5HA micelles are cross-linked with Cur through a phenol-alkyne click chemistry reaction, other substances are not introduced into the drug-loaded micelles. Therefore, the pH-responsive curcumin cross-linked micelles have improved stability, drug loading and therapeutic effects in vivo, have excellent drug delivery prospects, and provide new possibilities for the treatment of diseases such as AS. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 This is the synthetic route of OPDA-HEMA-5HA@Cur / SV.
[0019] Figure 2 NMR characterization of PDA-HEMA.
[0020] Figure 3 This is the NMR characterization of OPDA-HEMA.
[0021] Figure 4 This is the NMR characterization of OPDA-HEMA-5HA.
[0022] Figure 5 Infrared characterization of PDA-HEMA, OPDA-HEMA and OPDA-HEMA-5HA; A is the infrared spectrum of PDA-HEMA and OPDA-HEMA; B is the infrared spectrum of OPDA-HEMA-5HA and OPDA-HEMA.
[0023] Figure 6are the standard curve and drug concentration; A is the standard curve of Cur; B is the standard curve of SV; C is the drug concentration of single-drug and double-drug loaded micelles.
[0024] Figure 7 Figure 1 is the particle size scattering intensity and distribution, and electron microscope images of blank micelles, single-drug loaded micelles and dual-drug loaded micelles; A is the particle size scattering intensity and distribution of blank micelles; B is the electron microscope image of blank micelles; C is the particle size scattering intensity and distribution of single-drug loaded micelles; D is the electron microscope image of single-drug loaded micelles; E is the particle size scattering intensity and distribution of dual-drug loaded micelles; and F is the electron microscope image of dual-drug loaded micelles.
[0025] Figure 8 is the zeta potential of blank micelles and single-drug and double-drug loaded micelles.
[0026] Fig. 9 A is a potential monitoring diagram of blank micelles at different time intervals and a particle size monitoring diagram of blank micelles at different time intervals; B is a particle size monitoring diagram of blank micelles at different time intervals.
[0027] Fig.10 These are the potential and particle size monitoring diagrams of single drug-loaded micelles at different time intervals; A is the potential monitoring diagram of single drug-loaded micelles at different time intervals; B is the particle size monitoring diagram of single drug-loaded micelles at different time intervals.
[0028] Fig.11 Figure 1 is a graph showing the potential and particle size of dual-drug loaded micelles at different time intervals; Figure 1 is a graph showing the potential and particle size of dual-drug loaded micelles at different time intervals; Figure 1 is a graph showing the potential and particle size of dual-drug loaded micelles at different time intervals.
[0029] Fig.12 It is the cytotoxicity of Raw264.7 of OPDEA-HEMA-5HA, Cur+SV, SV, OPDA-HEMA-5HA@Cur and OPDA-HEMA-5HA@Cur / SV; wherein A is the cytotoxicity of RAW 264.7 of OPDEA-HEMA-5HA; B is the cytotoxicity of RAW 264.7 of Cur+SV, SV, OPDA-HEMA-5HA@Cur and OPDA-HEMA-5HA@Cur / SV.
[0030] Fig.13 Results of cell uptake experiments.
[0031] Fig.14Figure 3 is the transcellular delivery of OPDA-HEMA-5HA@Cur / NR in Raw264.7; A is the fluorescence intensity in the first group of RAW264.7 cells; B is the fluorescence intensity of the first group of RAW 264.7 cells after further incubation for 12 hours; C is the fluorescence intensity in the second group of RAW264.7 cells; and D is the fluorescence intensity in the third group of RAW 264.7 cells. DETAILED DESCRIPTION
[0032] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0033] The specific implementation of the present invention is described in detail below in conjunction with specific embodiments.
[0034] An embodiment of the present invention provides a method for preparing a pH-responsive curcumin cross-linked micelle, comprising the following steps:
[0035] Step 1, synthesis of PDA-HEMA: 2-2-bipyridine (0.064 g, 0.41 mmol) and CuCl (0.064 g, 0.65 mmol) were added to a multi-baked, vacuumed and argon-filled bottle in sequence, and the mixture was shaken back and forth to form a brick red complex, and then a monomer with a hydrophilic / hydrophobic molar ratio of 1.25:1 was added. The method is as follows: DEA (12 mL, 0.06 mol), HEMA (5.46 mL, 0.046 mol), ethyl 2-bromo-2-methylpropionate (270 μL, 1.8 mmol) and 8 mL N,N'-dimethylformamide (DMF) are added to a branch-mouth bottle in sequence, and then polymerized at 55 °C in an argon atmosphere for 3 h. After the reaction stops, it is exposed to the air and quenched by adding dichloromethane, and then passed through a neutral alumina column to remove copper ions. The filtrate is concentrated and then precipitated with cold petroleum ether, repeatedly recrystallized and purified, and finally dried in a vacuum drying oven for 24 h to obtain 5 g of PDA-HEMA.
[0036] Step 2, synthesis of OPDA-HEMA: add 30 mL of hydrogen peroxide to PDA-HEMA for oxidation, stir at room temperature for 2 h, then transfer the solution to a dialysis bag, dialyze with deionized water for 48 h, replace the dialysis water every 3-4 h, and freeze-dry to obtain a white flocculent product, i.e., OPDA-HEMA;
[0037] Step 3, Synthesis of OPDA-HEMA-5HA: Weigh 5-hexynoic acid (5-HA) (2.5 g, 0.0223 mol) and dissolve it in 30 mL of anhydrous dichloromethane, weigh oxalyl chloride (8.5 g, 0.067 mol) and dissolve it in 60 mL of anhydrous dichloromethane. Add the oxalyl chloride solution dropwise to 5-hexynoic acid at 0 ° C, and add 2-3 drops of DMF as a catalyst. After overnight reaction, the solution changes from colorless to black, and then the solvent and excess oxalyl chloride are dried and dissolved in 30 mL of anhydrous dichloromethane. Dissolve the prepared OPDA-HEMA (2 g) in dimethyl sulfoxide (DMSO), slowly add the chlorinated 5-hexynoic acid solution to OPDA-HEMA under argon atmosphere, and add triethylamine (1.8 mL, 0.013 mol). After the addition, the reaction was continued for 24 h, and then the solvent was removed, and the product was transferred to a dialysis bag (MWCO: 3500 Da), and then dialyzed with deionized water for 72 h to remove unreacted small molecules. After freeze-drying, 2.67 g of brown flocculent product, namely OPDA-HEMA-5HA, was obtained. The synthetic route of OPDA-HEMA-5HA is as follows Figure 1 shown.
[0038] The preparation methods of the blank micelles and the single-drug and double-drug loaded micelles mentioned in the following examples are as follows:
[0039] Blank micelles (OPDA-HEMA-5HA) were prepared by membrane dialysis.
[0040] -HEMA-5HA was dissolved in methanol, and the solution was added dropwise into ice water under ultrasonic treatment, and then dialyzed against deionized water for 24 h (MWCO: 3500 Da) to remove methanol by dialysis.
[0041] Single drug loaded micelles (OPDA-HEMA-5HA@Cur), i.e., single drug loaded curcumin (Cur) micelles, were prepared by a similar process. Specifically, OPDA-HEMA-5HA, Cur, and DMAP were dissolved in 1 mL of methanol, and after stirring at 37°C for 24 h, the mixed solution was added dropwise to 10 mL of ice water under ultrasonic treatment, and then dialyzed with deionized water for 24 h (MWCO: 3500Da), and methanol and DMAP were removed by dialysis.
[0042] Dual drug loaded micelles (OPDA-HEMA-5HA@Cur / SV), i.e., dual drug loaded micelles of curcumin (Cur) and simvastatin (SV), were prepared by a similar process. Specifically, OPDA-HEMA-5HA, Cur, simvastatin (SV) and DMAP were dissolved in 1 mL of methanol, and after stirring at 37°C for 24 h, the mixed solution was added dropwise to 10 mL of ice water under ultrasonic treatment, and then dialyzed with deionized water for 24 h (MWCO: 3500Da), and methanol and DMAP were removed by dialysis.
[0043] Example 1, NMR characterization;
[0044] Nuclear magnetic resonance spectroscopy (NMR) was used to characterize the PDA-HEMA, OPDA-HEMA and OPDA-
[0045] HEMA-5HA was characterized. PDA-HEMA was dissolved in CDCl3, OPDA-HEMA was dissolved in D2O, and OPDA-HEMA-5HA was dissolved in CH3DO. 1 H NMR spectra Figure 2 As shown. Peaks e and f are the methylene and methyl peaks in PDA, respectively, and peak k is the hydroxyl peak in HEMA, proving the successful synthesis of PDA-HEMA. 1 H NMR spectra Figure 3 Peaks e and f are the methylene and methyl peaks in OPDA, respectively, and peak k is the hydroxyl peak in HEMA, which proves the successful synthesis of OPDA-HEMA. 1 H NMR spectra Figure 4 As shown in the figure, peaks k, lm, and n are characteristic peaks of 5-hexynoic acid, which proves the successful synthesis of 5-HA.
[0046] Embodiment 2, Fourier transform infrared spectroscopy test;
[0047] The infrared spectra of polymers PDA-HEMA, OPDA-HEMA and OPDA-HEMA-5HA were measured by Fourier transform infrared spectrometer using potassium bromide tablet method. Figure 5 As shown in A and B. The FT-IR spectrum of OPDA-HEMA shows that the sharp peak at 2800 cm is N +_ O - The FT-IR spectrum of OPDA-HEMA-5HA showed that the peak at 3321 cm was the stretching vibration peak of -CH and the peak at 638 cm was the out-of-plane bending vibration peak of -CH, which proved the synthesis of OPDA-HEMA-5HA.
[0048] Example 3, Determination of in vitro drug loading and drug release curve;
[0049] Cur (curcumin) was dissolved in methanol to prepare a series of concentrations of 0.0044, 0.0061, 0.00736, 0.00968, and 0.0129 mmol / L, and its absorbance was measured using a UV-visible spectrophotometer (UV) at 25°C. With Cur concentration as the horizontal axis and Cur's UV absorbance as the vertical axis, a standard curve of Cur was established, as shown in Figure 1. Figure 6 As shown in A. SV (simvastatin) was dissolved in acetonitrile to prepare a series of concentrations of 0.01252, 0.025, 0.03, and 0.0625 mmol / L, and its absorbance was measured using a UV-visible spectrophotometer at 25°C. The standard curve of SV was established with SV concentration as the horizontal axis and SV ultraviolet absorbance as the vertical axis, as shown in Figure 1. Figure 6 As shown in B.
[0050] The prepared single-drug loaded micelle and dual-drug loaded micelle solutions were measured for their absorbance by UV, and their drug concentrations were determined according to the Cur and SV standard curves, such as Figure 6 As shown in C. Specifically, the single-drug loaded micelles (3 mL) loaded with Cur and the dual-drug loaded micelles (3 mL) loaded with Cur and SV were transferred to a dialysis bag (MWCO: 3500Da) and suspended in PBS containing 0.5% Tween 80 at pH = 5 and pH = 7.4, respectively. The total volume of each sample solution was 70 mL. Stirring was carried out under dark conditions at 37 ° C, and 3 mL samples were collected at specific time intervals (0.5, 1, 2, 4, 8, 10, 24, 30, 48, 72 h) and supplemented with fresh PBS. The content of Cur and SV was determined by UV. The cumulative release of the two drugs was the highest at pH 5 saline and the lowest at pH 7.4 saline. At pH 7.4, Cur was released slowly, and only about 47% of Cur and 51% of SV were released from OPDA-HEMA-5HA@Cur / SV at 72 h. In saline at pH 5.5, the release of Cur and SV increased to 69% and 82%, respectively. These results indicate that OPDA-HEMA-5HA@Cur / SV has the property of releasing drugs in response to low pH.
[0051] All tests were repeated three times under dark conditions, and the results were presented as average values. The drug encapsulation efficiency (EE%) and DL of Cur and SV-loaded single-drug and double-drug micelles were calculated as follows:
[0052]
[0053] The drug loading rate of OPDA-HEMA-5HA@Cur was 21.3% and the encapsulation efficiency was 82.1%.
[0054] The drug loading rate of Cur in OPDA-HEMA-5HA@Cur / SV was 18%, and the encapsulation efficiency was 82.2%. The drug loading rate of SV was 12.2%, and the encapsulation efficiency was 82.5%.
[0055] Example 4: Particle size, potential, morphology and stability test of blank micelles and single-drug and double-drug loaded micelles;
[0056] Under the condition of pH=7.4, the particle size scattering intensity and distribution of the prepared blank micelles and single-drug and double-drug loaded micelles were tested, respectively. Figure 7 As shown in A, C and E. The particle size of blank micelles is 110nm, single-drug micelles is 70nm, and dual-drug micelles is 150nm. The particle size of micelles was analyzed by dynamic light scattering (DLS), and the zeta potential was recorded by dynamic light scattering (DLS). The measurement was repeated three times and finally expressed as the mean ± standard deviation, as shown in Figure 8 As shown in Figure 2, the zeta potential of blank micelles and single-drug and double-drug loaded micelles is between -2 and -4 mv. In order to test the stability of blank micelles and single-drug and double-drug loaded micelles, the potential and particle size were monitored by DLS at multiple time intervals (0, 1, 3, 5, 7, and 10 days) at room temperature, as shown in Figure 2. Fig. 9 (blank micelles) Fig.10 (single drug-loaded micelle) and Fig.11 (Dual-drug loaded micelles). It was found that the size of the nanoparticles did not change significantly after being placed at room temperature for 14 days, which may be attributed to the stabilization of the nanoparticles by the presence of nitrogen oxide zwitterions. The freeze-dried micellar nanoparticles (blank micelles and single- and dual-drug loaded micelles) were dissolved in 10 mL of water to prepare a 1 mg / mL micellar solution, which was then dropped onto a carbon support film on a 200-mesh copper mesh using a syringe. After natural drying at room temperature, the overall morphology and particle size distribution of the nanoparticles were observed under a high-resolution transmission electron microscope, as shown in the figure. Figure 7 As shown in B, D and F. The nanomicelles are spherical, and the particle size is basically consistent with that measured by dynamic light scattering (DLS), which meets our predetermined requirements.
[0057] Example 5, cytotoxicity;
[0058] Cultivate RAW 264.7 cells to the logarithmic growth phase, and use the cells for MIT experiments. Cultivate RAW 264.7 until the culture medium turns yellow and the cells become round. Gently blow the cells directly with the culture medium to obtain a cell suspension. After centrifugation, blow the cells with 2 mL of culture medium. The inoculation cell density is 5×10 4 / mL, 5000 cells per well were cultured in a 96-well plate. To prevent edge volatilization effects, only the middle 60 wells were used and culture was continued for 24 hours. The groups included a blank group (culture medium), a negative control group (cells) and an experimental group (containing both cells and samples). The experimental group was set up by adding 100μL of nanoparticle suspension to each well of the well plate, with a final concentration of 4, 8, 16, 32, and 64μg / mL, and continued to be cultured in a 96-well plate for 24 hours. After the time was up, the culture medium and sample were discarded, the cells at the bottom were retained, washed twice with PBS, 100μL of serum-free culture medium was added to each well, and then 20μL of MTT solution (5mg / mL) was added to continue incubation for 4 hours, and finally the supernatant was poured out, retaining the cells and purple crystals at the bottom. 150μL DMSO was added to each well to fully dissolve the crystals, and oscillated for 10 minutes to mix. The absorbance at a wavelength of 490nm was detected by an enzyme reader. Fig.12 As shown in Figure A, after OPDEA-HEMA-5HA was incubated with RAW 264.7 for 24 hours, the cell death rate was no more than 20%, indicating that OPDEA-HEMA-5HA has good cell compatibility. Fig.12 As shown in Figure B, when the SV concentration exceeded 8 μg / mL, the survival rate of RAW 264.7 was significantly correlated with the SV concentration. The higher the SV concentration, the lower the cell survival rate. It is worth noting that when the SV concentration did not exceed 8 μg / mL, the survival rates of RAW 264.7 in the SV, Cur+SV, OPDA-HEMA-5HA@Cur and OPDA-HEMA-5HA@Cur / SV groups were all higher than 90%, proving that the toxicity of SV, Cur+SV, OPDA-HEMA-5HA@Cur and OPDA-HEMA-5HA@Cur / SV to RAW 264.7 cells was almost negligible. When the concentrations of SV and Cur+SV were higher than 8 μg / mL, the activity of RAW264.7 in the OPDA-HEMA-5HA@Cur and OPDA-HEMA-5HA@Cur / SV groups was always higher than that in the SV and Cur+SV groups, indicating that OPDA-HEMA-5HA@Cur and OPDA-HEMA-5HA@Cur / SV could reduce the toxicity of SV and Cur+SV to RAW 264.7.
[0059] The calculation equation of cell viability is as follows:
[0060]
[0061] Example 6, cellular uptake experiment;
[0062] An inverted fluorescence microscope was used to test the uptake of OPDA-HEMA-5HA@Cur / NR (fluorescent substance Nile Red NR was used instead of simvastatin to encapsulate the nanoparticles) by RAW 264.7 cells. RAW 264.7 cells were plated in 6-well plates (2x10 5 The cells were cultured in PBS (10 cells / well) for 24 h, and replaced with OPDA-HEMA-5HA@Cur / NR diluted with culture medium at a concentration of 10 μg / mL for 0.5, 2, and 6 h. The cells were washed with PBS three times, the cell nuclei were stained with Hoechst 33258 (10 mM), and the mitochondria were stained with MitoTrackerGreen FM at a concentration of 100 nM. The cells were then rinsed with PBS again and visualized using an inverted fluorescence microscope. The above experiments were performed three times. Fig.13 The intensity of Nile red fluorescence in RAW 264.7 cells in each group increased with time; for example, in each group, the red fluorescence intensity in the cells was higher at 6 h compared with 0.5 h and 2 h, indicating that the uptake behavior of RAW 264.7 cells for each group of drugs was time-dependent.
[0063] Example 7, transcellular transmission of RAW 264.7 (using Nile red instead of simvastatin);
[0064] RAW 264.7 cells in the logarithmic growth phase were pipetted back and forth with PBS to prepare a cell suspension, and the cell suspension was added to the culture dish, with 1.5×10 5 The cells were incubated for 12 h until the cells adhered to the wall and divided into three groups (numbered 1, 2, and 3). For the cells in group 1, OPDA-HEMA-5HA was added.
[0065] After incubation with Cur / NR for 5 h, the cells were washed twice with PBS, 1 mL of fresh culture medium was added, and the fluorescence intensity in the RAW 264.7 cells of group 1 was observed using an inverted fluorescence microscope. Fig.14 As shown in A, a strong red fluorescence signal was observed in A, indicating that a large amount of OPDA-HEMA-5HA@Cur / NR was taken up. After observation, the cells were returned to the cell culture incubator and incubated for 12 hours. The fluorescence intensity in the RAW 264.7 cells of group 1 was observed using an inverted fluorescence microscope. Fig.14 As shown in B, the fluorescence intensity in the cells of group 1 was observed to be weakened, indicating that a portion of OPDA-HEMA-5HA@Cur / NR was excreted from the cells. The culture medium incubated for 12 h in group 1 cells was collected and transferred to group 2 cells. The cells were incubated for 12 h, washed twice with PBS, and 1 mL of fresh culture medium was added. The fluorescence intensity in group 2 RAW 264.7 cells was observed using an inverted fluorescence microscope. Fig.14As shown in C, a strong fluorescence signal appeared in C, proving that the cells in group 1 can release OPDA-HEMA-5HA@Cur / NR into the culture medium through efflux, so it is taken up by the cells in group 2. After observation, the cells were returned to the cell culture incubator for another 12 hours. The culture medium incubated for 12 hours in group 2 cells was collected and transferred to group 3 cells, incubated for 12 hours, washed twice with PBS, and 1 mL of fresh culture medium was added. The fluorescence intensity in group 3 RAW 264.7 cells was observed using an inverted fluorescence microscope, as shown in Figure 2. Fig.14 As shown in D. We also observed OPDA-HEMA-5HA@
[0066] The red fluorescence of Cur / NR indicated that group 2 could continue to efflux OPDA-HEMA-5HA@Cur / NR into the culture medium through transcytosis and be taken up by cells in group 3. The above results showed that OPDA-HEMA-5HA@Cur / NR could achieve active transcytosis and transcellular transmission through continuous cellular endocytosis and efflux through selection.
[0067] The above are only preferred embodiments of the present invention. It should be pointed out that, for those skilled in the art, several modifications and improvements can be made without departing from the concept of the present invention. These should also be regarded as the protection scope of the present invention. These will not affect the effect of the implementation of the present invention and the practicality of the patent.
Claims
1. A method for preparing pH-responsive curcumin cross-linked micelles, characterized in that: The following steps are involved: Step 1, weigh 5-hexynoic acid and dissolve it in 30 mL of anhydrous dichloromethane, weigh oxalyl chloride and dissolve it in anhydrous dichloromethane; add the oxalyl chloride solution dropwise to the 5-hexynoic acid at 0°C, and add DMF as a catalyst, react overnight after the addition, the solution changes from colorless to black, and then the solvent and excess oxalyl chloride are dried and dissolved in 30 mL of anhydrous dichloromethane; dissolve OPDA-HEMA in DMSO, slowly add the chlorinated 5-hexynoic acid solution dropwise to OPDA-HEMA under an argon atmosphere, and add triethylamine, continue to react for 24 hours after the addition, then remove the solvent, transfer the product to a dialysis bag, dialyze with deionized water for 72 hours, and freeze-dry to obtain a brown flocculent product, i.e., OPDA-HEMA-5HA; Step 2, OPDA-HEMA-5HA, curcumin, simvastatin and DMAP were dissolved in 1 mL of methanol, and the mixed solution was added dropwise to 10 mL of ice water under ultrasonic treatment after stirring at 37°C for 24 h. The product was transferred to a dialysis bag and dialyzed with deionized water for 24 h to obtain OPDA-HEMA-5HA@Cur / SV; The synthesis steps of the OPDA-HEMA are as follows: adding 30% aqueous hydrogen peroxide solution to PDA-HEMA, stirring at room temperature, then transferring the solution to a dialysis bag with a MWCO of 3000Da, and then dialyzing with deionized water, changing it every 3-4 hours, and freeze-drying to obtain a white flocculent product, namely OPDA-HEMA; The synthesis steps of the PDA-HEMA are as follows: 2-2-bipyridine and CuCl are added in sequence to a multi-baked, vacuumed and argon-filled flask, and the flask is shaken back and forth to form a brick red complex, and then DEA, HEMA, ethyl 2-bromo-2-methylpropionate and DMF are added in sequence to the flask, and then polymerized at 55° C. for 3 hours in an argon atmosphere, and after the reaction stops, the flask is exposed to air and quenched by adding dichloromethane, and the filtrate is passed through a neutral alumina column to remove copper ions, and the filtrate is concentrated, and then precipitated with cold petroleum ether, repeatedly recrystallized and purified, and finally dried in a vacuum drying oven for 24 hours to obtain PDA-HEMA.
2. The method for preparing the pH-responsive curcumin cross-linked micelles according to claim 1, wherein: The cutoff capacity of the dialysis bag in step 1 and step 2 is 3500Da.
3. The method for preparing the pH-responsive curcumin cross-linked micelles according to claim 1, wherein In the synthesis step of PDA-HEMA, the ratio of 2-2-bipyridine to CuCl is 0.1-0.6:0.3-1.
4. A pH-responsive curcumin cross-linked micelle prepared according to the preparation method described in any one of claims 1 to 3.
5. Use of the pH-responsive curcumin cross-linked micelles according to claim 4 in preparing a drug delivery system for treating atherosclerosis.
